Explore News By Topic
05/15/2020
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in... Read More
05/15/2020
VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug
WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male Veterans with COVID-19. In a double-blind randomized controlled trial, VA scientists will compare the drug degarelix (trade name Firmagon) to a placebo... Read More
03/22/2020
Molecular Imaging Could Transform Management of People with Aggressive Cancer
VICTORIA, Australia, March 22, 2020: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for their patients, by determining the extent of disease spread at the time of diagnosis, a randomised... Read More
12/16/2019
FDA approves enzalutamide for metastatic castration-sensitive prostate cancer
December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More
12/16/2019
Winship study sheds light on immune control of cancer
Issued by: Emory University Woodruff Health Sciences Center New findings could provide doctors with vital clues about how the immune system prevents cancer from recurring. The study from Winship Cancer Institute of Emory University looked at whether immune cells were present in tumor samples removed from patients with kidney and... Read More
08/22/2019
The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners
The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research institutions. They will receive a total of $2.5 million to support cross-disciplinary pioneering research toward the goal of finding a... Read More
07/23/2019
Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine
Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports. An emerging class of drugs are made up of a radioactive particle that... Read More
06/26/2019
Newly defined cancer driver is Fast, Furious and Loud
Original Press Release Issued by: University of Michigan Medicine ANN ARBOR, Michigan — The Fast and the Furious movie franchise meets the Fast N’ Loud television series to define an oncogene that drives 35% of prostate cancers. A new study from researchers at the University of Michigan Rogel Cancer Center... Read More
05/22/2019
Black men less likely than nonblack patients to adopt active surveillance for low-risk prostate cancer
Original Press Release Issued by: Dana-Farber Cancer Institute Overall active surveillance rates are up, though the increase is significantly smaller for black patients Black men may be deterred by both socioeconomic factors and providers’ hesitation given concern for underlying aggressive disease BOSTON – At a time when a growing number of... Read More
05/06/2019
Gene mutation discovery linked to very poor survival in prostate cancer patients
Original Press Release Issued by: ICR (The Institute of Cancer Research) Scientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival – and which could be used to pick out patients for especially intensive treatment. Men with mutations in... Read More